Premium
Antigenicity and immunogenicity of Melan‐A/MART‐1 derived peptides as targets for tumor reactive CTL in human melanoma
Author(s) -
Romero Pedro,
Valmori Danila,
Pittet Mikael J.,
Zippelius Alfred,
Rimoldi Donata,
Lévy Frederic,
Dutoit Valérie,
Ayyoub Maha,
RubioGodoy Verena,
Michielin Olivier,
Guillaume Philippe,
Batard Pascal,
Luescher Immanuel F.,
Lejeune Ferdy,
Liénard Danielle,
Rufer Nathalie,
Dietrich PierreYves,
Speiser Daniel E.,
Cerottini JeanCharles
Publication year - 2002
Publication title -
immunological reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.839
H-Index - 223
eISSN - 1600-065X
pISSN - 0105-2896
DOI - 10.1034/j.1600-065x.2002.18808.x
Subject(s) - ctl* , antigen , immunogenicity , melanoma , immunology , biology , antigenicity , immunotherapy , cancer immunotherapy , cd8 , cytotoxic t cell , antibody , cancer research , immune system , in vitro , genetics
Summary: Some cancer patients mount spontaneous T‐ and B‐cell responses against their tumor cells. Autologous tumor reactive CD8 cytolytic T lymphocyte (CTL) and CD4 T‐cell clones as well as antibodies from these patients have been used for the identification of genes encoding the target antigens. This knowledge opened the way for new approaches to the immunotherapy of cancer. In this review, we describe the characterization of the structure‐function properties of the melanocyte/melanoma tumor antigen Melan‐A/MART‐1, the assessment of the T‐cell repertoire available against this antigen in healthy individuals, and the analysis of naturally acquired and/or vaccine‐induced CTL responses to this antigen in patients with metastatic melanoma.